Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial.

Ruinuo JiaTanyou ShanAnping ZhengYaowen ZhangPing LuGuifang ZhangFeng WangZhiqiao XuGuobao ZhengDongxia TangWeiguo ZhangWanying LiRuonan LiYibo GuoLina LiuXiaoyong LuoYingjuan ZhengZhiwei ChangQi-Ming WangXinshuai WangXiaozhi YuanGuoqiang KongShuoguo LiRuina YangDan ZhouJing RenWeijiao YinJingxia LiJunqian ZhangZiqi WangManxi ShengBingyi XuLiuyan LiXiaoyi LiuZhihao LuLixin WanFuyou ZhouShegan Gao

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

Capecitabine or XELOX did not significantly improve the 2-year OS rate over PF in DCRT for inoperable locally advanced ESCC. Capecitabine showed a lower incidence of grade ≥3 AEs than PF did.

Keyphrases

locally advanced
phase ii study
rectal cancer
open label
neoadjuvant chemotherapy
squamous cell carcinoma
radiation therapy
phase iii
double blind
phase ii
clinical trial
risk factors
randomized controlled trial
placebo controlled